BioCentury
ARTICLE | Clinical News

AXL1717: Interim Phase I/II data

April 18, 2011 7:00 AM UTC

Interim data from 35 patients in the Phase I portion of the ongoing, open-label, dose-escalation, Swedish Phase I/II AXL-001 trial showed that AXL1717 was well tolerated. Additionally, Axelar said an ...